Journal article

Gender effects on brain changes in early-onset psychosis

Marta Rapado-Castro, Cali F Bartholomeusz, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Soraya Otero, Inmaculada Baeza, Carmen Moreno, Montserrat Graell, Joost Janssen, Nuria Bargallo, Christos Pantelis, Manuel Desco, Celso Arango

European Child and Adolescent Psychiatry | SPRINGER | Published : 2015

Abstract

Progressive loss of cortical gray matter (GM) and increase of cerebrospinal fluid (CSF) have been reported in early-onset psychosis (EOP). EOP typically begins during adolescence, a time when developmental brain trajectories differ by gender. This study aimed to determine gender differences in progression of brain changes in this population. A sample of 61 (21 females) adolescents with a first psychotic episode and a matched sample of 70 (23 females) controls underwent both baseline and 2-year follow-up anatomical brain imaging assessments. Regional GM and CSF volumes were obtained using automated methods based on the Talairach's proportional grid system. At baseline, only male patients show..

View full abstract

Grants

Awarded by RETICS


Awarded by Regional Government


Awarded by NHMRC Australian-based Senior Principal Research Fellowship


Awarded by NARSAD Distinguished Investigator Award (US)


Awarded by NHMRC Program Grant



Funding Acknowledgements

This work was supported by the Spanish Ministry of Economy and Competitiveness. Instituto de Salud Carlos III, CIBERSAM, RETICS RD06/0011 (REM-TAP Network), Fundacion Alicia Koplowitz, Fundacion Mutua Madrilena, by Grants PI02/1248, PI05/0678, PI09/01442, PI12/1303, G03/032, Regional Government (S2010/BMD-2422 AGES) and by the European Union Structural Funds (Madrid, Spain). This work was partially supported by Spain's Ministry of Science and Innovation through CDTI's CENIT Program (AMIT Project). Dr. Rapado-Castro has received a Health Research Sara Borrell Fellowship from the Spanish Ministry of Economy and Competitiveness, an Alicia Koplowitz Grant for Short-Term Placements from the Alicia Koplowitz Foundation and an IiSGM Fellowship Award for Short-term Placements from the Health Research Institute from the Hospital Gregorio Maranon (IiSGM) (Madrid, Spain). Dr. Rapado-Castro has also received grant support from the Fundacion Alicia Koplowitz. Dr. Bartholomeusz has received a National Health and Medical Research Council (NHMRC) Australian-based Clinical Research Fellowship and a John and Betty Lynch Fellowship from the Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne. Dr. Gonzalez-Pinto is employed by the University of the Basque Country and has been a consultant for the Ministry of Science of Spain and the Basque Government. Dr. Gonzalez-Pinto also gives conferences, acts as consultant to or receives grants from Lilly, Janssen, MSD, Lundbek, AstraZeneca, Almirall, Sanofi Aventis, BMS, Novartis and Pfizer. Dr. Baeza has received support from Otsuka for attending a conference. Dr. Moreno has served as a consultant to AstraZeneca, Otsuka, Bristol-Myers Squibb and Janssen. Dr. Moreno has also received grant support from the Fundacion Alicia Koplowitz, Instituto de Salud Carlos III and European Union Structural Funds. Professor Pantelis has received a NHMRC Australian-based Senior Principal Research Fellowship (ID: 628386), NARSAD Distinguished Investigator Award (US; Grant ID: 18722), and NHMRC Program Grant (ID: 566529); he has received grant support from Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca and has provided consultancy to Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca, Pfizer, Schering Plough, Lundbeck. He has undertaken investigator initiated studies supported by Eli Lilly, Hospira, Janssen Cilag and Astra Zeneca. Dr. Arango. has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundacion Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovacion, Ministerio de Sanidad, Ministerio de Economia y Competitividad, Mutua Madrilena, Otsuka, Pfizer, Roche, Servier, Shire, Takeda and Schering Plough. The rest of the authors declare no conflicts of interest.